STOCK TITAN

Atricure Inc - ATRC STOCK NEWS

Welcome to our dedicated news page for Atricure (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atricure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atricure's position in the market.

Rhea-AI Summary
AtriCure, Inc. to release Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.54%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
conferences
Rhea-AI Summary
AtriCure, Inc. will release its second quarter 2023 financial results on July 25, 2023. The company will host an audio webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences
Atricure Inc

Nasdaq:ATRC

ATRC Rankings

ATRC Stock Data

1.43B
45.98M
3.08%
102.25%
4.99%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Mason

About ATRC

atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.